Phase I Study of S-1 plus Fractional Cisplatin as Adjuvant Chemotherapy for Advanced Gastric Cancer in an Outpatient Setting (KOGC-03)

作者：Takahashi Tsunehiro^*; Saikawa Yoshiro; Fukuda Kazumasa; Nakamura Rieko; Wada Norihito; Kawakubo Hirofumi; Takeuchi Hiroya; Takaishi Hiromasa; Icitagawa Yuko

来源：Anticancer Research, 2015, 35(1): 467-471.

DOI：10.1200/jco.2015.33.3_suppl.157

• Gastric cancer
• adjuvant chemotherapy
• outpatient setting
• S-1
• cisplatin

Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer. Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m(2) (level I); 25 mg/m(2) (level 2); 30 mg/m(2) (level.3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery. Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively. Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.

• 出版日期2015-1